Drug Profile
Research programme: neurological injury therapeutics - PresSura Neuro
Alternative Names: EU-C-002Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Roche
- Developer PresSura Neuro
- Class
- Mechanism of Action Neurokinin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain injuries; Craniocerebral trauma; Reperfusion injury
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Reperfusion-injury(Prevention) in Australia
- 28 Apr 2019 No recent reports of development identified for preclinical development in Brain injuries in Australia
- 28 Apr 2019 No recent reports of development identified for preclinical development in Craniocerebral-trauma in Australia